Cancer Immunology
26%
off

Cancer Immunology

3.5 (2 ratings by Goodreads)
Edited by  , Edited by 

Free delivery worldwide

Available. Dispatched from the UK in 4 business days
When will my order arrive?

Description

CYTOTOXIC T LYMPHOCYTES-INDUCTION AND ACTIVATION ...124 EPSTEIN BARR VIRUS ASSOCIATED TUMOURS ...125 Immunoblastic lymphomas ...126 Burkitt's lymphoma ...127 NPC and Hodgkin's lymphoma ...127 Vaccines for EBV associated malignancies ...128 HUMAN PAPILLOMA VIRUS (HPV) ASSOCIATED TUMOURS ...129 T cell responses against HPV ...130 Cytotoxic T cell responses in HPV infection ...130 Vaccines and clinical trials ...132 Recombinant viral vaccines ...132 Peptide vaccines ...133 Bacterial fusion protein vaccines ...134 Potential Pitfalls for CTL based immunotherapy of CaCX ...134 PROSPECTS FOR OTHER VIRALL Y ASSOCIATED CANCERS ...135 Hepatitis viruses and primary liver cancer ...135 Human herpes virus 8 and Kaposi's sarcoma ...136 Human T lymphotropic virus and adult T cell leukaemia ...136 Emerging tumour viruses ...137 CONCLUDING REMARKS ...137 ACKNOWLEDGEMENTS ...138 REFERENCES ...139 Chapter 8 ...147 The immune response to oncogenic fusion proteins LORENA PASSONI & CARLO GAMBACORTI-PASSERINI xiii INTRODUCTION ...147 BCRlABL ...149 CML immunotherapy ...150 Specific recognition of the bcr/abl protein ...150 CML vaccination ...152 FUSION PROTEINS AND TUMOUR ESCAPE ...1
52 CONCLUDING REMARKS ...154 REFERENCES ...154 Chapter 9 ...157 Immunological significance ofhsp70 in tumor rejection ANTOINE MENORET INTRODUCTION ...157 PROGRESSOR AND REGRESSOR TUMORS ...157 CO-SEGREGATION OF EXPRESSION OF THE INDUCIBLE HSP70, BUT NOT OF THE CONSTITUTIVE HSC70, WITH A REGRESSIVE PHENOTYPE ...159 IMMUNIZATION WITH TUMOR-DERIVED HEAT SHOCK PROTEIN OF 70 KDA (HSP70IHSC70), NA TURALL Y OR ARTIFICIALLY COMPLEXED WITH ANTIGENIC PEPTIDES ...161 DIFFERENCE OF PEPTIDE BINDING DOMAINS BETWEEN THE INDUCIBLE HSP70 AND CONSTITUTIVE HSC70 ...163 XIV IMPLICATION FOR IMMUNOTHERAPY OF CANCER AND BEYOND ...165 ACKNOWLEDGMENTS ...166 REFERENCES ...166 Chapter 10 ...
show more

Product details

  • Hardback | 253 pages
  • 165.1 x 241.3 x 20.3mm | 544.32g
  • Dordrecht, Netherlands
  • English
  • 2001 ed.
  • XXI, 253 p.
  • 0792370074
  • 9780792370079

Table of contents

Contributers. 1. Immunogenicity of tumour associated antigens; S. Mian, et al. 2. Recognition of human tumours: cancer/testis antigens; A.F. Kirkin, et al. 3. Recognition of human tumors: SEREX expression cloning to identify tumour antigens; U. Sahin, et al. 4. Recognition of human tumours: melanoma differentiation antigens; J. Zeuthen, A.F. Kirkin. 5. Carcinoembryonic Antigen as a Vaccine Target; J. Schlom, et al. 6. MUC1 mucin as a target for immunotherapy of cancer: Muc1 based immunotherapeutic strategies; M. Soares, O.J. Finn. 7. Recognition of human tumours: viral antigens as immunological targets for cytotoxic T Cells; S. Man. 8. The immune response to oncogenic fusion proteins; L. Passoni, C. Gambacorti-Passerini. 9. Immunological significance of hsp70 in tumor rejection; A. Menoret. 10. Anti-idiotypic vaccination; L.G. Durrant, et al. 11. Genetically modified tumour cells for cancer immunization; S. Todryk, et al. 12. Antibody targeted therapy; delivery of radionuclides, toxins and drugs; A. Murray, et al. 13. Escape mechanisms in tumour immunity; G. Pawelec. Index.
show more

Rating details

2 ratings
3.5 out of 5 stars
5 0% (0)
4 50% (1)
3 50% (1)
2 0% (0)
1 0% (0)
Book ratings by Goodreads
Goodreads is the world's largest site for readers with over 50 million reviews. We're featuring millions of their reader ratings on our book pages to help you find your new favourite book. Close X